Teva Raises Guidance As Generics Enjoy Solid Growth In Q2
Biosimilars Business Boosted By Adalimumab Launch In US Ahead Of Ustekinumab Opportunity
Teva has upped its expectations for 2024 after the second quarter brought a major boost for its worldwide generics business and positive signs for biosimilars in the US.
